Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Heron Therapeutics Inc (HRTX) USD0.01

Sell:$15.30 Buy:$15.75 Change: $0.20 (1.29%)
NASDAQ:2.13%
Market closed |  Prices as at close on 12 August 2020 | Switch to live prices |
Sell:$15.30
Buy:$15.75
Change: $0.20 (1.29%)
Market closed |  Prices as at close on 12 August 2020 | Switch to live prices |
Sell:$15.30
Buy:$15.75
Change: $0.20 (1.29%)
Market closed |  Prices as at close on 12 August 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Contact details

Address:
4242 Campus Point Ct Ste 200
SAN DIEGO
92121
United States
Telephone:
+1 (858) 2514400
Website:
www.herontx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
HRTX
ISIN:
US4277461020
Market cap:
$1.41 billion
Shares in issue:
90.86 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Barry Quart
    President, Chief Executive Officer, Director
  • Robert Hoffman
    Chief Financial Officer, Senior Vice President - Finance
  • Kimberly Manhard
    Executive Vice President - Drug Development, Director
  • John Poyhonen
    Executive Vice President, Chief Commercial Officer
  • Thomas Ottoboni
    Senior Vice President - Pharmaceutical and Translational Sciences, Chief Scientific Officer
  • Anita Gupta
    Senior Vice President - Medical Strategy and Government Affairs
  • Michael Mathews
    Senior Vice President - Pain Franchise
  • David Szekeres
    Chief Legal, Business and Administrative Officer
  • Sean Ristine
    Vice President - Human Resources
  • John Arthur
    Vice President - Manufacturing and Supply

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.